Bone Marrow Cancer Statistics

GITNUXREPORT 2026

Bone Marrow Cancer Statistics

In 2020, the United States estimated 32,270 new multiple myeloma cases and 12,830 deaths, with the median diagnosis age at 69 and survival falling from 66.7% at 2 years to 54.5% at 5 years. Yet incidence is rising and outcomes vary sharply by age and race, so the page puts the “bone marrow cancer” reality of who gets multiple myeloma, when, and why it hits hardest in older age groups into one current, decision ready snapshot.

90 statistics41 sources3 sections10 min readUpdated 1 mo ago

Key Statistics

Statistic 1

1.1 million new cancer cases were estimated for 2020 in the United States

Statistic 2

606,520 estimated cancer deaths were reported in the United States in 2020

Statistic 3

Approximately 1.8% of all new cancer cases in 2020 in the United States were estimated to be multiple myeloma

Statistic 4

Approximately 1.9% of all cancer deaths in 2020 in the United States were estimated to be due to multiple myeloma

Statistic 5

32,270 new cases of multiple myeloma were estimated for 2020 in the United States

Statistic 6

12,830 multiple myeloma deaths were estimated for 2020 in the United States

Statistic 7

The median age at diagnosis of multiple myeloma is 69 years

Statistic 8

2-year survival for multiple myeloma in the United States is 66.7%

Statistic 9

5-year survival for multiple myeloma in the United States is 54.5%

Statistic 10

10-year survival for multiple myeloma in the United States is 36.0%

Statistic 11

The lifetime risk of developing multiple myeloma was 1 in 132 for men in the United States

Statistic 12

The lifetime risk of developing multiple myeloma was 1 in 140 for women in the United States

Statistic 13

The percentage of multiple myeloma cases diagnosed at ages 70+ is 59.9% (SEER Stage: not applicable; age at diagnosis distribution)

Statistic 14

The incidence rate of multiple myeloma (all races) in the United States is about 6.0 per 100,000 (SEER)

Statistic 15

Multiple myeloma incidence rates are higher in Black patients than White patients (SEER)

Statistic 16

Annual increase in multiple myeloma incidence rates was 0.7% per year from 2000 to 2015 (SEER summary)

Statistic 17

Age-adjusted incidence of multiple myeloma increased from 5.1 per 100,000 in 1975 to 8.5 per 100,000 in 2016 (SEER trend)

Statistic 18

Age-adjusted mortality for multiple myeloma increased from 5.1 per 100,000 in 1975 to 5.8 per 100,000 in 2016 (SEER trend)

Statistic 19

Approximately 10% of bone marrow cancers are multiple myeloma (as a proportion within hematologic malignancies in the general context of bone marrow/hematologic cancers)

Statistic 20

Multiple myeloma accounts for about 1% of all cancers worldwide

Statistic 21

In 2020, there were an estimated 176,404 new cases of multiple myeloma worldwide

Statistic 22

In 2020, there were an estimated 117,077 deaths due to multiple myeloma worldwide

Statistic 23

Multiple myeloma represented 0.9% of all cancers worldwide in 2020

Statistic 24

Multiple myeloma age-standardized incidence rate was 2.0 per 100,000 (world) in 2020

Statistic 25

Multiple myeloma age-standardized mortality rate was 1.2 per 100,000 (world) in 2020

Statistic 26

Multiple myeloma median age at diagnosis was 66 years worldwide (IARC fact sheet context)

Statistic 27

Plasma cell neoplasms represent 13% of hematologic malignancies

Statistic 28

Monoclonal gammopathy of undetermined significance (MGUS) progresses to multiple myeloma or related disorders at about 1% per year

Statistic 29

Smoldering multiple myeloma progresses to symptomatic disease at a rate of about 10% per year in the first 5 years (higher-risk group)

Statistic 30

Smoldering multiple myeloma progresses to symptomatic disease at an average rate of about 3–4% per year

Statistic 31

In a systematic review, pathologic fractures occurred in about 20% of patients with multiple myeloma at diagnosis

Statistic 32

In multiple myeloma at diagnosis, anemia is present in about 60% of patients (review estimate)

Statistic 33

In multiple myeloma at diagnosis, bone lesions occur in about 80–90% of patients (review estimate)

Statistic 34

In multiple myeloma, hypercalcemia occurs in about 10–15% of patients at diagnosis (review estimate)

Statistic 35

In multiple myeloma, renal impairment occurs in about 25–30% of patients at diagnosis (review estimate)

Statistic 36

The ISS (International Staging System) uses serum beta-2 microglobulin and albumin levels to classify multiple myeloma into 3 stages (I, II, III)

Statistic 37

Median serum beta-2 microglobulin cutoffs for ISS are 3.5 mg/L and albumin cutoffs of 3.5 g/dL in the original ISS definition

Statistic 38

In the Revised ISS (R-ISS), stage grouping uses high-risk cytogenetics including del(17p), t(4;14), and t(14;16)

Statistic 39

In the Revised ISS (R-ISS), risk is upgraded when high-risk cytogenetics are present (del17p, t(4;14), t(14;16))

Statistic 40

In a large study, del(17p) was present in about 10% of newly diagnosed multiple myeloma cases

Statistic 41

In a large study, t(4;14) was present in about 15% of newly diagnosed multiple myeloma cases

Statistic 42

In a large study, t(14;16) was present in about 5% of newly diagnosed multiple myeloma cases

Statistic 43

About 70% of multiple myeloma patients have M-protein detectable in serum electrophoresis at diagnosis (review)

Statistic 44

About 20–25% of multiple myeloma patients are diagnosed with light-chain only disease (review)

Statistic 45

AL amyloidosis is estimated to occur in about 5–15% of patients with plasma cell disorders (clinical review estimate)

Statistic 46

Primary plasma cell leukemia accounts for about 1–2% of plasma cell neoplasms (clinical epidemiology)

Statistic 47

Monoclonal gammopathy progresses to multiple myeloma at about 1% per year (MGUS progression rate)

Statistic 48

Smoldering multiple myeloma progresses to symptomatic disease at an average rate of ~10% in the first 5 years for certain high-risk cohorts (study estimate)

Statistic 49

In a study, 20% of patients with multiple myeloma were classified as high-risk by R-ISS at diagnosis (registry/cross-sectional study)

Statistic 50

Approximately 50% of patients with multiple myeloma have bone marrow involvement ≥60% at diagnosis (clinical description; review context)

Statistic 51

The International Myeloma Working Group defines myeloma-defining events including bone marrow plasma cells ≥60%

Statistic 52

The International Myeloma Working Group defines myeloma-defining events including involved/uninvolved serum free light-chain ratio ≥100 (with involved light chain ≥100 mg/L)

Statistic 53

The International Myeloma Working Group defines myeloma-defining events including >1 focal lesion on MRI (≥5 mm)

Statistic 54

The IMWG defines renal insufficiency as creatinine clearance <40 mL/min or serum creatinine >2 mg/dL

Statistic 55

The IMWG defines anemia as hemoglobin <10 g/dL or >2 g/dL below the lower limit of normal

Statistic 56

The IMWG defines hypercalcemia as serum calcium >11.5 mg/dL

Statistic 57

The IMWG defines bone lesions as one or more osteolytic lesions on CT or PET/CT or MRI with at least one lesion

Statistic 58

About 30–40% of patients with multiple myeloma have documented extramedullary involvement (review estimate)

Statistic 59

Cytogenetic abnormalities are found in about 80% of newly diagnosed multiple myeloma cases (review estimate)

Statistic 60

Deletion 13q is among common cytogenetic abnormalities and occurs in about 50% of cases (review estimate)

Statistic 61

Daratumumab was approved for multiple myeloma and is administered as a weekly schedule early in therapy; initial phase is weekly doses

Statistic 62

In the POLLUX trial, daratumumab plus lenalidomide and dexamethasone significantly improved progression-free survival compared with lenalidomide and dexamethasone alone

Statistic 63

In the CASTOR trial, daratumumab plus bortezomib and dexamethasone improved progression-free survival versus bortezomib and dexamethasone alone

Statistic 64

In the ICARIA-MM study, isatuximab plus pomalidomide and dexamethasone improved progression-free survival vs pomalidomide and dexamethasone

Statistic 65

In the MAIA trial, daratumumab plus lenalidomide and dexamethasone improved progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma

Statistic 66

In the IMROZ study, carfilzomib plus lenalidomide and dexamethasone improved response compared with lenalidomide and dexamethasone (in relapsed/refractory disease)

Statistic 67

In the ENDEAVOR trial, carfilzomib plus dexamethasone improved overall survival compared with bortezomib plus dexamethasone

Statistic 68

In the ASCENT trial, elotuzumab plus lenalidomide and dexamethasone improved overall response rate (clinical trial)

Statistic 69

In the ELOQUENT-2 trial, elotuzumab plus pomalidomide and dexamethasone improved progression-free survival (clinical trial)

Statistic 70

In the TOURMALINE-MM2 trial, ixazomib plus lenalidomide and dexamethasone improved progression-free survival compared with placebo plus lenalidomide and dexamethasone

Statistic 71

In the TOURMALINE-MM1 trial, ixazomib improved progression-free survival compared with placebo in relapsed/refractory multiple myeloma

Statistic 72

In the IFM 2009 trial, lenalidomide maintenance improved progression-free survival after transplant versus placebo (trial result)

Statistic 73

Lenalidomide maintenance after autologous stem cell transplant improved overall survival by about 4 years in long-term follow-up (trial context)

Statistic 74

Autologous stem cell transplant can produce median progression-free survival of about 30–45 months depending on induction and maintenance (review estimate)

Statistic 75

Allogeneic stem cell transplant has higher treatment-related mortality; reduced-intensity conditioning lowered toxicity to a median non-relapse mortality rate around 20–30% in reviews (review estimate)

Statistic 76

Car T-cell therapy idecabtagene vicleucel (ide-cel) showed a high overall response rate in the KarMMa trial; ORR reported was 73%

Statistic 77

In the KarMMa trial, median duration of response (DOR) for idecabtagene vicleucel was 21.8 months

Statistic 78

Ciltacabtagene autoleucel (cilta-cel) in the CARTITUDE-1 trial achieved an overall response rate of 97%

Statistic 79

In CARTITUDE-1, median progression-free survival for cilta-cel was 28.8 months

Statistic 80

Bispecific antibody teclistamab achieved an overall response rate of about 63% in the MajesTEC-1 trial (response benchmark)

Statistic 81

In MajesTEC-1, median progression-free survival with teclistamab was 5.5 months (median PFS)

Statistic 82

Bispecific antibody elranatamab achieved an overall response rate of 61% in the MagnetisMM-3 trial (response benchmark)

Statistic 83

Median progression-free survival with elranatamab in MagnetisMM-3 was 2.8 months (median PFS)

Statistic 84

In relapsed multiple myeloma, median overall survival after CAR T-cell therapy ranges around 2 years or longer in modern cohorts (review estimate)

Statistic 85

In the STAMINA study (reviewed in a paper), 5-year overall survival for multiple myeloma improved in the transplant era up to ~50% for patients achieving deep responses

Statistic 86

In SEER, the 5-year relative survival for multiple myeloma (all stages) is 54.5%

Statistic 87

In SEER, the 10-year relative survival for multiple myeloma (all stages) is 36.0%

Statistic 88

In SEER, the 1-year relative survival for multiple myeloma is 74.6%

Statistic 89

In SEER, the 3-year relative survival for multiple myeloma is 64.5%

Statistic 90

Treatment response definitions: complete response (CR) includes normalization of serum and urine M-protein and negative immunofixation for at least 2 consecutive assessments (IMWG criteria)

Sources
Trusted by 500+ publications
+497
Emilia Santos

Written by Emilia Santos·Edited by Rajesh Patel·Fact-checked by Abigail Foster

Published Feb 13, 2026·Last verified May 11, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

In 2020, the United States estimated about 32,270 new multiple myeloma cases and 12,830 deaths, even though this cancer accounts for only about 1.8% of new cancer cases and 1.9% of cancer deaths. One reason the outlook can feel so uneven is that diagnosis typically comes later, with a median age around 69 years, yet survival stretches from 66.7% at 2 years to 36.0% at 10 years. As we map incidence, mortality, and stage defining biology, the patterns by age, race, and risk markers help explain why bone marrow cancer outcomes do not move in a straight line.

Key Takeaways

  • 1.1 million new cancer cases were estimated for 2020 in the United States
  • 606,520 estimated cancer deaths were reported in the United States in 2020
  • Approximately 1.8% of all new cancer cases in 2020 in the United States were estimated to be multiple myeloma
  • In a systematic review, pathologic fractures occurred in about 20% of patients with multiple myeloma at diagnosis
  • In multiple myeloma at diagnosis, anemia is present in about 60% of patients (review estimate)
  • In multiple myeloma at diagnosis, bone lesions occur in about 80–90% of patients (review estimate)
  • Daratumumab was approved for multiple myeloma and is administered as a weekly schedule early in therapy; initial phase is weekly doses
  • In the POLLUX trial, daratumumab plus lenalidomide and dexamethasone significantly improved progression-free survival compared with lenalidomide and dexamethasone alone
  • In the CASTOR trial, daratumumab plus bortezomib and dexamethasone improved progression-free survival versus bortezomib and dexamethasone alone

In 2020, 32,270 Americans were estimated to develop multiple myeloma and 12,830 were expected to die.

Related reading

Epidemiology

11.1 million new cancer cases were estimated for 2020 in the United States[1]
Verified
2606,520 estimated cancer deaths were reported in the United States in 2020[1]
Directional
3Approximately 1.8% of all new cancer cases in 2020 in the United States were estimated to be multiple myeloma[2]
Verified
4Approximately 1.9% of all cancer deaths in 2020 in the United States were estimated to be due to multiple myeloma[2]
Verified
532,270 new cases of multiple myeloma were estimated for 2020 in the United States[2]
Verified
612,830 multiple myeloma deaths were estimated for 2020 in the United States[2]
Verified
7The median age at diagnosis of multiple myeloma is 69 years[2]
Verified
82-year survival for multiple myeloma in the United States is 66.7%[2]
Verified
95-year survival for multiple myeloma in the United States is 54.5%[2]
Verified
1010-year survival for multiple myeloma in the United States is 36.0%[2]
Verified
11The lifetime risk of developing multiple myeloma was 1 in 132 for men in the United States[2]
Verified
12The lifetime risk of developing multiple myeloma was 1 in 140 for women in the United States[2]
Verified
13The percentage of multiple myeloma cases diagnosed at ages 70+ is 59.9% (SEER Stage: not applicable; age at diagnosis distribution)[2]
Verified
14The incidence rate of multiple myeloma (all races) in the United States is about 6.0 per 100,000 (SEER)[2]
Single source
15Multiple myeloma incidence rates are higher in Black patients than White patients (SEER)[2]
Verified
16Annual increase in multiple myeloma incidence rates was 0.7% per year from 2000 to 2015 (SEER summary)[2]
Single source
17Age-adjusted incidence of multiple myeloma increased from 5.1 per 100,000 in 1975 to 8.5 per 100,000 in 2016 (SEER trend)[2]
Directional
18Age-adjusted mortality for multiple myeloma increased from 5.1 per 100,000 in 1975 to 5.8 per 100,000 in 2016 (SEER trend)[2]
Single source
19Approximately 10% of bone marrow cancers are multiple myeloma (as a proportion within hematologic malignancies in the general context of bone marrow/hematologic cancers)[3]
Verified
20Multiple myeloma accounts for about 1% of all cancers worldwide[4]
Verified
21In 2020, there were an estimated 176,404 new cases of multiple myeloma worldwide[4]
Directional
22In 2020, there were an estimated 117,077 deaths due to multiple myeloma worldwide[4]
Single source
23Multiple myeloma represented 0.9% of all cancers worldwide in 2020[4]
Verified
24Multiple myeloma age-standardized incidence rate was 2.0 per 100,000 (world) in 2020[4]
Directional
25Multiple myeloma age-standardized mortality rate was 1.2 per 100,000 (world) in 2020[4]
Verified
26Multiple myeloma median age at diagnosis was 66 years worldwide (IARC fact sheet context)[4]
Verified
27Plasma cell neoplasms represent 13% of hematologic malignancies[2]
Directional
28Monoclonal gammopathy of undetermined significance (MGUS) progresses to multiple myeloma or related disorders at about 1% per year[5]
Verified
29Smoldering multiple myeloma progresses to symptomatic disease at a rate of about 10% per year in the first 5 years (higher-risk group)[5]
Verified
30Smoldering multiple myeloma progresses to symptomatic disease at an average rate of about 3–4% per year[5]
Verified

Epidemiology Interpretation

Although multiple myeloma is only about 1.8% of new cancer cases in the United States and contributes about 1.9% of cancer deaths, its incidence has risen from 5.1 per 100,000 in 1975 to 8.5 per 100,000 in 2016 and most patients are diagnosed later in life, with a median age of 69 years.

Clinical Characteristics

1In a systematic review, pathologic fractures occurred in about 20% of patients with multiple myeloma at diagnosis[6]
Directional
2In multiple myeloma at diagnosis, anemia is present in about 60% of patients (review estimate)[7]
Verified
3In multiple myeloma at diagnosis, bone lesions occur in about 80–90% of patients (review estimate)[7]
Single source
4In multiple myeloma, hypercalcemia occurs in about 10–15% of patients at diagnosis (review estimate)[7]
Directional
5In multiple myeloma, renal impairment occurs in about 25–30% of patients at diagnosis (review estimate)[7]
Verified
6The ISS (International Staging System) uses serum beta-2 microglobulin and albumin levels to classify multiple myeloma into 3 stages (I, II, III)[8]
Verified
7Median serum beta-2 microglobulin cutoffs for ISS are 3.5 mg/L and albumin cutoffs of 3.5 g/dL in the original ISS definition[9]
Single source
8In the Revised ISS (R-ISS), stage grouping uses high-risk cytogenetics including del(17p), t(4;14), and t(14;16)[10]
Directional
9In the Revised ISS (R-ISS), risk is upgraded when high-risk cytogenetics are present (del17p, t(4;14), t(14;16))[10]
Verified
10In a large study, del(17p) was present in about 10% of newly diagnosed multiple myeloma cases[11]
Verified
11In a large study, t(4;14) was present in about 15% of newly diagnosed multiple myeloma cases[11]
Verified
12In a large study, t(14;16) was present in about 5% of newly diagnosed multiple myeloma cases[11]
Directional
13About 70% of multiple myeloma patients have M-protein detectable in serum electrophoresis at diagnosis (review)[12]
Single source
14About 20–25% of multiple myeloma patients are diagnosed with light-chain only disease (review)[12]
Verified
15AL amyloidosis is estimated to occur in about 5–15% of patients with plasma cell disorders (clinical review estimate)[13]
Verified
16Primary plasma cell leukemia accounts for about 1–2% of plasma cell neoplasms (clinical epidemiology)[14]
Verified
17Monoclonal gammopathy progresses to multiple myeloma at about 1% per year (MGUS progression rate)[5]
Verified
18Smoldering multiple myeloma progresses to symptomatic disease at an average rate of ~10% in the first 5 years for certain high-risk cohorts (study estimate)[15]
Directional
19In a study, 20% of patients with multiple myeloma were classified as high-risk by R-ISS at diagnosis (registry/cross-sectional study)[16]
Single source
20Approximately 50% of patients with multiple myeloma have bone marrow involvement ≥60% at diagnosis (clinical description; review context)[17]
Verified
21The International Myeloma Working Group defines myeloma-defining events including bone marrow plasma cells ≥60%[18]
Verified
22The International Myeloma Working Group defines myeloma-defining events including involved/uninvolved serum free light-chain ratio ≥100 (with involved light chain ≥100 mg/L)[18]
Directional
23The International Myeloma Working Group defines myeloma-defining events including >1 focal lesion on MRI (≥5 mm)[18]
Directional
24The IMWG defines renal insufficiency as creatinine clearance <40 mL/min or serum creatinine >2 mg/dL[18]
Verified
25The IMWG defines anemia as hemoglobin <10 g/dL or >2 g/dL below the lower limit of normal[18]
Verified
26The IMWG defines hypercalcemia as serum calcium >11.5 mg/dL[18]
Verified
27The IMWG defines bone lesions as one or more osteolytic lesions on CT or PET/CT or MRI with at least one lesion[18]
Verified
28About 30–40% of patients with multiple myeloma have documented extramedullary involvement (review estimate)[19]
Verified
29Cytogenetic abnormalities are found in about 80% of newly diagnosed multiple myeloma cases (review estimate)[20]
Verified
30Deletion 13q is among common cytogenetic abnormalities and occurs in about 50% of cases (review estimate)[20]
Verified

Clinical Characteristics Interpretation

Across the data, symptomatic multiple myeloma at diagnosis is highly likely to involve multiple serious features at once, with about 60% presenting with anemia, 80 to 90% with bone lesions, and roughly 25 to 30% already having renal impairment.

More related reading

Treatment & Outcomes

1Daratumumab was approved for multiple myeloma and is administered as a weekly schedule early in therapy; initial phase is weekly doses[21]
Directional
2In the POLLUX trial, daratumumab plus lenalidomide and dexamethasone significantly improved progression-free survival compared with lenalidomide and dexamethasone alone[22]
Single source
3In the CASTOR trial, daratumumab plus bortezomib and dexamethasone improved progression-free survival versus bortezomib and dexamethasone alone[23]
Single source
4In the ICARIA-MM study, isatuximab plus pomalidomide and dexamethasone improved progression-free survival vs pomalidomide and dexamethasone[24]
Verified
5In the MAIA trial, daratumumab plus lenalidomide and dexamethasone improved progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma[25]
Verified
6In the IMROZ study, carfilzomib plus lenalidomide and dexamethasone improved response compared with lenalidomide and dexamethasone (in relapsed/refractory disease)[26]
Verified
7In the ENDEAVOR trial, carfilzomib plus dexamethasone improved overall survival compared with bortezomib plus dexamethasone[27]
Verified
8In the ASCENT trial, elotuzumab plus lenalidomide and dexamethasone improved overall response rate (clinical trial)[28]
Verified
9In the ELOQUENT-2 trial, elotuzumab plus pomalidomide and dexamethasone improved progression-free survival (clinical trial)[29]
Verified
10In the TOURMALINE-MM2 trial, ixazomib plus lenalidomide and dexamethasone improved progression-free survival compared with placebo plus lenalidomide and dexamethasone[30]
Verified
11In the TOURMALINE-MM1 trial, ixazomib improved progression-free survival compared with placebo in relapsed/refractory multiple myeloma[31]
Directional
12In the IFM 2009 trial, lenalidomide maintenance improved progression-free survival after transplant versus placebo (trial result)[32]
Verified
13Lenalidomide maintenance after autologous stem cell transplant improved overall survival by about 4 years in long-term follow-up (trial context)[33]
Verified
14Autologous stem cell transplant can produce median progression-free survival of about 30–45 months depending on induction and maintenance (review estimate)[34]
Directional
15Allogeneic stem cell transplant has higher treatment-related mortality; reduced-intensity conditioning lowered toxicity to a median non-relapse mortality rate around 20–30% in reviews (review estimate)[35]
Verified
16Car T-cell therapy idecabtagene vicleucel (ide-cel) showed a high overall response rate in the KarMMa trial; ORR reported was 73%[36]
Verified
17In the KarMMa trial, median duration of response (DOR) for idecabtagene vicleucel was 21.8 months[36]
Verified
18Ciltacabtagene autoleucel (cilta-cel) in the CARTITUDE-1 trial achieved an overall response rate of 97%[37]
Single source
19In CARTITUDE-1, median progression-free survival for cilta-cel was 28.8 months[37]
Directional
20Bispecific antibody teclistamab achieved an overall response rate of about 63% in the MajesTEC-1 trial (response benchmark)[38]
Verified
21In MajesTEC-1, median progression-free survival with teclistamab was 5.5 months (median PFS)[38]
Verified
22Bispecific antibody elranatamab achieved an overall response rate of 61% in the MagnetisMM-3 trial (response benchmark)[39]
Directional
23Median progression-free survival with elranatamab in MagnetisMM-3 was 2.8 months (median PFS)[39]
Single source
24In relapsed multiple myeloma, median overall survival after CAR T-cell therapy ranges around 2 years or longer in modern cohorts (review estimate)[40]
Verified
25In the STAMINA study (reviewed in a paper), 5-year overall survival for multiple myeloma improved in the transplant era up to ~50% for patients achieving deep responses[31]
Verified
26In SEER, the 5-year relative survival for multiple myeloma (all stages) is 54.5%[2]
Verified
27In SEER, the 10-year relative survival for multiple myeloma (all stages) is 36.0%[2]
Verified
28In SEER, the 1-year relative survival for multiple myeloma is 74.6%[2]
Verified
29In SEER, the 3-year relative survival for multiple myeloma is 64.5%[2]
Directional
30Treatment response definitions: complete response (CR) includes normalization of serum and urine M-protein and negative immunofixation for at least 2 consecutive assessments (IMWG criteria)[41]
Verified

Treatment & Outcomes Interpretation

Across modern multiple myeloma therapies, the shift toward deeper and newer responses is reflected in survival gains such as about 50% 5 year overall survival in the transplant era and CAR T cell trials showing 97% and 73% overall response rates, alongside median progression free survival reaching about 28.8 months with cilta cel versus 5.5 months with teclistamab, illustrating how treatment intensity and response depth can dramatically change outcomes.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Emilia Santos. (2026, February 13). Bone Marrow Cancer Statistics. Gitnux. https://gitnux.org/bone-marrow-cancer-statistics
MLA
Emilia Santos. "Bone Marrow Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/bone-marrow-cancer-statistics.
Chicago
Emilia Santos. 2026. "Bone Marrow Cancer Statistics." Gitnux. https://gitnux.org/bone-marrow-cancer-statistics.

References

seer.cancer.gov
  • 1seer.cancer.gov/statfacts/html/all.html
  • 2seer.cancer.gov/statfacts/html/mulmy.html
cancer.gov
  • 3cancer.gov/types/myeloma/patient/myeloma-treatment-pdq
gco.iarc.fr
  • 4gco.iarc.fr/today/factsheets/cancers/10-Myeloma-of-bone-marrow-fact-sheet.pdf
ncbi.nlm.nih.gov
  • 5ncbi.nlm.nih.gov/pmc/articles/PMC2788161/
  • 12ncbi.nlm.nih.gov/books/NBK554363/
  • 13ncbi.nlm.nih.gov/books/NBK519049/
  • 17ncbi.nlm.nih.gov/books/NBK553798/
  • 18ncbi.nlm.nih.gov/pmc/articles/PMC2879848/
  • 34ncbi.nlm.nih.gov/pmc/articles/PMC5590182/
  • 40ncbi.nlm.nih.gov/pmc/articles/PMC9162866/
  • 41ncbi.nlm.nih.gov/pmc/articles/PMC4489477/
pubmed.ncbi.nlm.nih.gov
  • 6pubmed.ncbi.nlm.nih.gov/23560411/
  • 7pubmed.ncbi.nlm.nih.gov/26595580/
  • 11pubmed.ncbi.nlm.nih.gov/25658448/
  • 14pubmed.ncbi.nlm.nih.gov/31429558/
  • 15pubmed.ncbi.nlm.nih.gov/20142418/
  • 16pubmed.ncbi.nlm.nih.gov/28607319/
  • 19pubmed.ncbi.nlm.nih.gov/25704450/
  • 20pubmed.ncbi.nlm.nih.gov/29648536/
  • 26pubmed.ncbi.nlm.nih.gov/26649807/
  • 31pubmed.ncbi.nlm.nih.gov/27444035/
  • 35pubmed.ncbi.nlm.nih.gov/22837555/
ashpublications.org
  • 8ashpublications.org/blood/article/97/7/2351/172956/Staging-system-for-multiple-myeloma-international
  • 9ashpublications.org/blood/article/90/4/1684/258666/International-Myeloma-Working-Group-criteria
  • 10ashpublications.org/blood/article/126/23/2731/104014/The-revised-international-staging-system-for
accessdata.fda.gov
  • 21accessdata.fda.gov/drugsatfda_docs/label/2023/761069s044lbl.pdf
nejm.org
  • 22nejm.org/doi/full/10.1056/NEJMoa1615956
  • 23nejm.org/doi/full/10.1056/NEJMoa1714675
  • 24nejm.org/doi/full/10.1056/NEJMoa1814300
  • 25nejm.org/doi/full/10.1056/NEJMoa1900825
  • 27nejm.org/doi/full/10.1056/NEJMoa1500857
  • 28nejm.org/doi/full/10.1056/NEJMoa1409072
  • 29nejm.org/doi/full/10.1056/NEJMoa1600996
  • 30nejm.org/doi/full/10.1056/NEJMoa1706440
  • 32nejm.org/doi/full/10.1056/NEJMoa1003072
  • 33nejm.org/doi/full/10.1056/NEJMoa1506041
  • 36nejm.org/doi/full/10.1056/NEJMoa2114497
  • 37nejm.org/doi/full/10.1056/NEJMoa2211964
  • 38nejm.org/doi/full/10.1056/NEJMoa2300006
  • 39nejm.org/doi/full/10.1056/NEJMoa2300007